AstraZeneca, “with second dose less risk of rare thrombosis”

Vaccine AstraZeneca, no more cases of rare thrombosis were recorded with the second dose. This is the conclusion of a study published in ‘The Lancet’, funded and conducted by the Anglo-Swedish company, which analyzes rare thrombotic events reported around the world. “All events with thrombocytopenic thrombotic syndrome (TTS) that occurred within 14 days of administration of the first or second dose of AstraZeneca vaccine up to 30 April were also included,” explain the authors. Well, “13 cases of TTS have been identified after the second dose”, in people “between the ages of 45 and 85”, of which “8 were women”. “As of April 25, it is estimated that approximately 5.6 million people have received the full course of the vaccine in Europe” Vaxzevria *. “The estimated rate of TTS within 14 days of the second dose was 2.3 per million vaccinated. For the first dose it was 8.1 per million vaccinated, based on 399 cases of Tss identified after the first dose of AZ and approximately 49.2 million first doses administered, with 45.2% of doses administered in the UK and 54.8% in Europe. ”